Clinical biochemistry
-
Clinical biochemistry · Jul 2019
Analytical characterization of the Siemens Dimension EXL high-sensitivity cardiac troponin I assay.
Siemens Healthcare Diagnostics has four commercially available assays on different analytical platforms using different methodologies to generate signal. We assessed the analytical performance of the Dimension EXL hs-cTnI assay (LOCI method) across different matrices and compared it to two different acridinium ester-based hs-cTnI assays (ADVIA Centaur and Abbott ARCHITECT). ⋯ The Siemens EXL hs-cTnI assay meets the analytical criteria for a high-sensitivity assay, with assay specific cutoffs important to maximize clinical performance.
-
Clinical biochemistry · Jul 2019
ReviewData science, artificial intelligence, and machine learning: Opportunities for laboratory medicine and the value of positive regulation.
Artificial intelligence (AI) and data science are rapidly developing in healthcare, as is their translation into laboratory medicine. Our review article presents an overview of the data science domain while discussing the reasons for its emergence. We also present several perspectives of its applications in clinical laboratories, along with potential ethical challenges related to AI and data science.
-
Clinical biochemistry · Jun 2019
Biomarker panel in sleep apnea patients after an acute coronary event.
Acute coronary syndrome (ACS) is a major cause of death and closely related with obstructive sleep apnea (OSA). Our hypothesis is that several cardiovascular-related biomarkers could have a differential prognostic value for ACS severity in patients with OSA, and could also help (individually or combined) in the detection of OSA in patients after a coronary event. ⋯ NCT01335087 (clinicaltrials.gov).
-
Clinical biochemistry · Apr 2019
Explore potential plasma biomarkers of acute respiratory distress syndrome (ARDS) using GC-MS metabolomics analysis.
The aim of this study was to analyse the metabolomics of patients with acute respiratory distress syndrome (ARDS) for the identification of metabolic markers with potential diagnostic and prognostic value. ⋯ Plasma metabolomics may improve our understanding of ARDS biology. Specific products related to hypoxia may serve as early biomarkers for ARDS prediction, while the metabolites with significant correlations with partial pressure of arterial oxygen (PaO2)/percentage of inspired oxygen (FiO2) may play a role in determining ARDS severity. This study suggests that metabolomic analysis in patients at risk of ARDS or those with early ARDS may provide new insight into disease pathogenesis or prognosis.